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ABSTRACT 
Objective: The present study was carried out to identify the peptide epitopes with high immunogenicity in the surface proteins of four pathogenic 
Ebola virus (viz. Bundibugyo virus, Sudan virus, Tai Forest virus and Zaire Ebola virus) using modern reverse vaccinology approach through in silico 
analysis of proteome for use as Ebola vaccine candidates.  
Methods: Hexapeptide epitopes based on maximum hydrophilicity were identified in eight surface proteins which were separated from a pool of 
160 Ebola virus proteins using a covariant discriminant function and the Mahalanobis D2 statistic. Heptapeptide B cell epitopes were predicted 
from the surface proteins using the AbDesigner algorithm. Immunogenicity score of each identified epitope was estimated on the basis of 
hydropathy index and Chou-Fasman conformation.  
Results: Four continuous (linear) hexapeptide epitopes namely RRKRRD (position 497-502), DEDDED (489-494), RRTRRE (497-502) and KTGKKG 
(221-226) with maximum hydrophilicity score were identified from different surface proteins for use as Ebola vaccine components. For use as B cell 
epitopes eight linear heptapeptide epitopes viz. PTSPPQD (418-424) and SHYEPPN (385-391) against Bundibugyo virus, PDYDDCH (309-315) and 
DYDDCHS (310-316) against Sudan virus, QPKCNPN (508-514) against Tai Forest virus and EYTYPDS (685-691), HLGLDDQ (365-371) and 
DQEKKIL (370-376) against Zaire Ebola virus with high immunogenicity were identified from different surface proteins of Ebola virus.  
Conclusion: Four hexapeptide and eight heptapeptide epitopes can be loaded along with T cell or B cell signal peptides in virus like particle (vlp) or 
formulated as subunit vaccine by pharmaceutical industry to raise humoral immunity against Ebola virus in African population as well as in other 
human populations across the globe as therapeutics in the same way the Hepatitis B therapeutic vaccine based on multiple peptide-epitopes was 
designed nearly a decade ago.  
Keywords: Ebola, Vaccine, Peptide epitopes, Immunogenicity, Hydrophilicity, Chou-Fasman conformation. 
 
INTRODUCTION  
Ebola virus disease (EVD) broke out as a fatal disease in the recent 
past in Africa, particularly in Sudan, Congo, Guinea, Sierra Leone, 
Liberia and Nigeria. The virus is fast spreading to new areas. Within 
two to three days of contracting the virus, patients show the 
symptoms of hemorrhagic fever, sore throat and headache, loss of 
appetite, chest pain, hiccups and shortness of breath, muscle pain, 
nausea and diarrhea. Functioning of liver and kidneys is decreased 
and the affected people begin to bleed either internally or externally. 
The disease has very high mortality rate, often killing between 50 
and 90% of the affected people. The first reported case of EVD dates 
back to 1976 in Sudan where a lady Mayinga N died within a few 
days of contracting the virus. From 1976 through 2013, fewer than 
1000 people per year have been infected. But the largest outbreak of 
Ebola virus has been during July-August 2014 in West Africa. This 
recent outbreak has created renewed interests among the scientists 
to take up the research initiative to combat the virus.  
Till todate there is no specific treatment for the disease. Efforts are 
continuing to develop vaccines against Ebola virus, but none exists 
till todate. Effective vaccines against Ebola virus is the most essential 
medical intervention to save thousands of African people from 
frequent Ebola outbreak. Development of proteome-based peptide 
vaccine could bring an immediate relief in this noble endeavor.  
EVD is caused by four pathogenic viruses in the genus Ebola viz. 
Bundibugyo Virus (BDBV), Sudan Virus (SUDV), Tai Forest Virus 
(TAFV) and Ebola Virus (EBOV, formerly Zaire Ebola Virus). Ebola 
has the highest pathogenicity and responsible for the largest number 
of outbreaks in history. The virus is acquired upon contact with the 
blood or bodily fluids of an infected animal like fruit bat or monkey. 
Once human infection occurs, the disease may spread between 
people through medical equipment (syringe, needle), semen, oral 
exposure etc.  
The virions of Ebola virus contain linear, nonsegmented, single-
stranded RNA genome of size 19kb. The genome does not possess a 
5’-cap and is non-polyadenylated and non-covalently linked to a 
protein. The Ebola virus genetics is difficult to study due to its 
virulent nature and affects the researchers who handle them.  
Over the past two centuries, quite a good number of vaccines have 
been used for the treatment and control of infectious diseases such 
as smallpox [1-4], diphtheria and poliomyelitis [5-6]. Attempts are 
being made to develop effective vaccines for eliminating several 
major pathogens of human populations like malaria. Measles, acute 
respiratory infection and HIV. It is thus imperative to develop novel 
vaccine formulations to combat the sophisticated pathogens and to 
promote the right type of protective immunity in human 
populations.  
In general, the traditional vaccines include either whole inactivated 
or live attenuated microbes. However, these can be unsafe and might 
produce several side effects, such as inflammation of tissues [7]. In 
contrast, the vaccines that contain purified or recombinant 
macromolecules of pathogens such as surface proteins or 
polysaccharides seem to have minimal side effects [8]. Moreover, the 
particulate delivery systems, such as liposomes, emulsions, 
immunostimulatory complexes and virus like particles, augment 
antigen-specific immune responses [9]. In case of pathogens where 
no vaccine is yet available or difficult to develop on the basis of the 
pathogen’s polysaccharide (coat protein) pool, it really makes sense 
to attempt the development of a peptide-based multiple-epitope 
loaded vaccine as a preventive measure against the pathogen for 
immediate application using the modern tools of proteomics. 
Though such proteome derived vaccine may not be so effective in 
boosting up immunity as the polysaccharide-based vaccine, the 
former would certainly reduce the risk of contracting the virus and 
slow down the spread of the virus in a geographical region.  
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To generate immunological response to a pathogen, the B cells 
play a key role by making antibodies against the viral antigens, 
some developing into memory B cells and performing the role of 
antigen presenting cells. B cells are continuously produced in the 
bone marrow. B cells are distinct from other lymphocytes, such as 
T cells and natural killer cells (NK), by virtue of the presence of a 
protein on the outer surface known as a B cell receptor (BCR). This 
specialized receptor protein allows a B cell to bind to a specific 
antigen. When the BCR matches the antigen, the B cell proliferates 
and secretes a free form of antibodies. The B cell receptors evolve 
and change throughout the B cell lifespan. The large B cells, often 
called plasma B cells, secrete large amounts of antibodies which 
destroy the microbes and make them easier targets for 
phagocytes. Plasma B cells contain large amounts of rough 
endoplasmic reticulum (ER), responsible for synthesizing the 
specific antibody in the cytoplasm. Plasma B cells are generally 
short lived and undergo apoptosis when the inciting agent i. e. the 
antigen of the pathogen is eliminated.  
B cell recognizes the cognate antigen in its native form in the blood 
or lymph using B cell receptor or membrane bound immunoglobulin. 
In contrast, the T cells usually recognize their cognate antigen in a 
processed form as a peptide fragment presented by an antigen-
presenting cell’s MHC (major histocompatibility complex) molecule 
to the T cell receptor. A critical feature of the B cells is that they can 
be activated in a T-cell dependent or independent manner. Detailed 
discussion on the molecular biology of B cell activation is beyond the 
scope of this paper. B cells, in fact, constitute a part in the humoral 
immunity of the adaptive (acquired) immune system. Humoral 
immunity is the antibody-mediated immune system. B cells also 
release the cytokines (proteins) which are used in signaling the 
immune regulatory functions.  
In view of the dire need of a vaccine against Ebola, the present 
investigation was taken up to identify the potential peptide antigens 
from the extracellular/surface proteins of different pathogenic 
strains of Ebola and to estimate their immunogenicity using the 
tools of bioinformatics. The identified peptide antigens with very 
high immunogenicity could be packaged in a vaccine formulation by 
the pharmaceutical industry for immediate application to raise 
protective immunity against Ebola virus in African population to 
save valuable lives.  
 
Table 1: Hexapeptide epitopes with antigenic propensity in four pathogenic Ebola viruses (Hopp & Woods approach) 
Ebola Virus No. of 
proteins  
analyzed 













Spike glycoprotein RRTRRE 497-502 14.6 5.25 
gi|499104260 
|AGL73474.1  
Glycoprotein RRTREE 497-502 14.6 5.25 
Sudan Virus 66 gi|165940957 
|ABY75323.1 
Matrix protein KTGKKG 221-226 8.6 5.45 
gi|81933487 
|Q5XX06.1 























RRTRRE 497-502 14.6 5.25 
 
MATERIALS AND METHODS  
Materials 
All the complete protein sequences for each of the four pathogenic 
Ebola viruses viz. Bundibugyo Virus (30), Sudan virus (66), Tai 
Forest Virus (20) and Zaire Ebola Virus (50) were retrieved from 
NCBI database (http: //www. ncbi. nlm. nih. gov).  
Methods  
Using an in-house perl script, the surface or extracellular proteins of 
each virus were determined out of five probable subcellular 
locations of prokaryotic proteins on the basis of a covariant 
discriminant function algorithm and Mahalanobis D2 statistic [10]. 
This method requires the determination of the inverse of a 20x20 
matrix for each subcellular location. When the determinant of the 
matrix was found to be zero for the matrix, Eigen value-Eigen vector 
system was used to find the inverse matrix for ascertaining the 
actual subcellular location of each protein.  
The surface proteins or extracellular proteins of each virus were 
separated using bioinformatics tool. The linear antigenic 
determinant (hexapeptide epitope) of each surface protein was 
determined based on the highest hydrophilicity score of each 
hexapeptide from N terminal end of the protein in a sliding window 
for one amino acid in the protein [11]. Using this technique, one 
linear hexapeptide epitope for each protein was precisely predicted 
with exact location in the protein. The antigenic propensity, the 
hydrophilicity score and the number of aliphatic amino acids 
(capable of forming interactions with other molecules) of each 
hexapeptide epitope were estimated for each surface protein.  
The B cell epitopes (linear heptapeptides) of each surface protein 
were determined using the primary structure based algorithm [12] 
along with its antigenic propensity. In a protein more than one B cell 
epitope could be found. The antigenic propensity, the hydrophilicity 
score and the number of aliphatic amino acids for each B cell 
heptapeptide epitope were calculated. Not all epitopes in a protein 
induce high humoral immunity i. e. produce a high antibody titers 
against the protein antigens. In order to find out all the continuous B 
cell epitopes of a protein with high immunogenicity, the AbDesigner 
algorithm [13] was used to estimate the hydropathy index, and the 
Chou-Fasman conformational parameter (of beta turn) which were 
further utilized for estimating the immunogenicity of the 7-mer 
heptapeptide epitope.  
The surface proteins having potential to generate the efficient 
epitopes for use as vaccines were further analyzed following in silico 
approach for the polar/non-polar amino acids, hydrophilicity, Gravy 
score, aromaticity, net charge at neutral pH (7.0) and pI (isoelectric 
point) to elucidate the interrelationships among the surface proteins 
for each biochemical character.  
RESULTS AND DISCUSSIONS 
Multi-epitope peptide-based vaccines represent a powerful 
approach to overcome the immunodominance and thus 
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simultaneously generate broad immune responses [14-15]. A 
synthetic-peptide vaccine approach is ideally suited to meet the 
requirements [16] where different sequences can be easily included 
in a single dose. Vaccines can be altered to include the emerging 
variant sequences.  
 
Fig. 1: Antigenic propensity, hydrophilicity and aliphatic amino 
acids in hexapeptide epitopes of Ebola virus 
The emerging vaccine informatics and immunoinformatics-based 
vaccine design strategies were reviewed [17]. Multi-epitope peptide-
loaded virus like particles containing peptide epitopes HBx (52-60), 
HBx (92-100) and HBx (115-123) derived from the x protein of 
Hepatitis B virus demonstrated significantly higher immunogenicity 
than any single responsive epitope against the hepatocellular 
carcinoma [14]. Research work has revealed that the developing 
countries are at more risk for viral diseases like hepatitis C virus 
[18]. Taking both the risks and the costs of immunization into 
consideration, the researchers suggested that a peptide-based 
vaccine derived from reverse vaccinology approach may be a 
reasonable prophylactic protection as well as a therapeutic 
intervention in already infected patients. 
They reported two immunogenic HLA-A2-restricted decapeptide 
core epitopes i. e. core 35-44 (YLLPRRGPRL) and core 131-140 
(ADLMGYIPLV) to induce peptide-specific cytotoxic T lymphocytes 
(CTL).  
In fact, the development and successful administration of peptide 
vaccine in human against Hepatitis B virus using genome derived 
approach more than a decade ago ushered in a new era of 
vaccinology. These vaccines were prepared primarily on the basis of 
information generated from the bioinformatic analysis of viral 
proteomes within two years of whole genome sequencing of the 
pathogen.  
 
Table 2: Immunogenicity (Ig) analysis of hexapeptide epitopes in four Ebola viruses (Hopp & Woods approach) 
Ebola Virus  Accession No. Hexapeptide 
Epitope 
No. of Aliphatic amino 
acids 











RRTRRE 0 8.20 0.92 7.54 
gi|499104260 
|AGL73474.1  
RRTREE 0 8.20 0.92 7.54 
Sudan Virus gi|165940957 
|ABY75323.1 
KTGKKG 5 6.70 1.18 7.91 
gi|81933487 
|Q5XX06.1 
KTGKKG 5 6.70 1.18 7.91 
Tai Forest Virus gi|1041218 
|AAB37093.1 
RRKRRD 1 8.73 1.05 9.17 
gi|302315373 
|YP_3815426.1 





DEDDED 0 8.00 1.22 9.76 
gi|436409443 
|AGB56839.1 
RRTRRE 0  8.20 0.92 7.54 
 
Thus, vaccine formulation, either peptide or DNA vaccine, using 
bioinformatics tools is a risk-free and rapid process to design the 
effective vaccines against many fatal diseases, subject to the 
availability of whole genome or proteome of the particular candidate 
pathogens against which vaccines need to be developed. From the 
analysis of 160 proteins in the present study across four pathogenic 
Ebola viruses (Bundibugyo, Sudan, Tai Forest and Zaire Ebola virus), 
a total of eight surface proteins, two from each virus, were identified 
as potential proteins for deriving the epitopes using a covariant 
discriminant algorithm and Mahalanobis D2 statistic.  
 
Fig. 2: Immunogenicity of hexapeptide epitopes in Ebola virus 
Hexapeptide Epitope Analysis  
The antigenic determinants in proteins contain a continuous or 
linear sequence of 6-10 amino acids. It was observed that 
hexapeptide antigenic determinants in proteins induce more 
effective immune response in host against pathogens [11]. One 
hexapeptide antigenic determinant (epitope) based on maximum 
hydrophilicity value was detected for each surface protein using the 
method [11]. Hydrophilicity and antigenic propensity of the 
hexapeptide epitopes were estimated based on amino acid sequence 
(Table 1). Two hexapeptide epitopes namely RRKRRD (position 497-
502) and DEDDED (489-494) recorded the highest hydrophilicity 
score of 18.0 with antigenic propensity of 5.29 and 5.17, respectively 
against Tai Forest virus and Zaire Ebola virus (Fig 1). But the 
hexapeptide epitope RRTRRE (497-502) recorded maximum 
hydrophilicity score of 14.6 with antigenic propensity of 5.25 for 
Bundibugyo and Zaire Ebola virus. Similarly, for Sudan virus the 
hexapeptide KTGKKG (221-226) was identified with maximum 
hydrophilicity score of 8.6 and antigenic propensity of 5.45. These 
hexapeptide sequences are linear 6-mer sequences identified in a 6-
mer sliding window moving by one amino acid from N terminal end 
of each surface protein. These peptides having the highest 
hydrophilicity score would tend to orient on the surface region of 
the protein structure and might interact with other molecules to 
elicit specific antibodies.  
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For successful use of peptide epitopes as potential vaccine 
candidates, the epitopes must be highly immunogenic. The 
immunogenicity of four hexapeptide epitopes was estimated using 
the immunogenicity score (Ig) derived from hydropathy index and 
Chou-Fasman conformation for beta turn [13]. Immunogenicity 
analysis revealed that two hexapeptide epitopes DEDDED (9.76) and 
RRKRRD (9.17) recorded very high immunogenicity score for Zaire 
Ebola and Tai Forest virus (Fig 2). But the epitope KTGKKG was 
estimated to have immunogenicity score of 7.91 in case of Sudan 
virus whereas the epitope RRTRRE recorded the immunogenicity 
score of 7.54 for Bundibugyo and Zaire Ebola virus. The peptide 
epitopes capable of binding to immunoglobulin protein complexes 
are usually enriched in aliphatic amino acids (i. e. A, G, I, K, L, V & M). 
Amongst four epitopes, the epitopes KTGKKG and RRKRRD had 5 
and 1 aliphatic amino acids, respectively whereas the epitopes 
DEDDED and RRTRRE contained no aliphatic amino acid.  
Heptapeptide (7-mer) Epitope Analysis as B cell Epitope  
Bioinformatic approach can be applied for the identification of linear 
heptapeptide B cell epitopes, which are potential vaccine candidates, 
located in the surface proteins. For each Ebola virus four B cell 
epitopes were identified with their corresponding position in the 
complete protein (Table 3).  
Hydrophilicity score and antigenic propensity were estimated for 
each epitope (Fig 3). Hydrophilicity score of epitopes ranged from -
5.30 (SSYYHTT, position 210-216) to 8.60 (DQEKKIL, 370-376) 
whereas the antigenic propensity varied from 6.99 (PSTPPQD, 418-
424) to 7.38 (DPSSYYH, 208-214) (Fig 4). The epitopes with positive 
hydrophilicity coupled with high antigenic propensity could be the 
potential candidates in subunit vaccine formulation.  
Thus the heptapeptide epitopes PSTPPQD and SHYEPPN (385-391) 
could be used as B cell epitopes against Bundibugyo virus whereas 
two overlapping heptapeptides PDYDDCH (309-315) and DYDDCHS 
(310-316) against Sudan virus.  
Similarly, the heptapeptide QPKCNPN (508-514) could be a strong B 
cell epitope against Tai Forest virus but three heptapeptides namely 
EYTYPDS (685-691), HLGLDDQ (365-371) and DQEKKIL (370-376) 
are potential vaccine candidates against Zaire Ebola virus. 
Immunogenicity analysis of the B cell epitopes revealed that 
immunogenicity score of heptapeptides was in the range 5.28 – 8.58 
(Table 4). In fact, all the identified epitopes recorded high 
immunogenicity score suggesting that these heptapeptides would 
raise humoral immunity when successfully administered as antigens 
in carrier particles. The B cell epitopes PTSPPQD, SHYEPPN, 
PDYDDCH, DYDDCHS and QPKCNPN were estimated to have 
immunogenicity score more than 8.0 for Bundibugyo, Sudan and Tai 
Forest virus. The epitopes EYTYPDS for Zaire Ebola virus recorded 
relatively low immunogenicity score (7.57). The epitopes HLGLDDQ 
and DQEKKIL had low immunogenicity score 5.86 and 5.28 for Zaire 
Ebola virus. From the comparison of aliphatic amino composition in B 
cell epitopes, it was evident that the epitopes DQEKKIL, HLGLDDQ and 
QPKCNPN contained 4, 3 and 1 aliphatic amino acids, respectively.  
 
Fig. 3: Antigenic propensity, hydrophilicity and aliphatic amino 
acids in B cell epitopes of Ebola virus 
 
Table 3: Proteins having potential B cell epitopes for Ebola vaccine development 













Spike glycoprotein PSTPPQD 418-424 3.10 6.99 
SHYEPPN 385-391 0.70 6.99 
gi|499104260 
|AGL73474.1 
Glycoprotein  SHTTPSP 430-436 -0.70 7.07 
DPSSYYH 208-214 -1.50 7.38 
Sudan Virus gi|165940957 
|ABY75323.1 
Matrix protein PDYDDCH 309-315 5.20 7.34 
DYDDCHS 310-316 5.50 7.29 
gi|81933487 
|Q5XX06.1 
VP 40 protein QGIPDHP 140-146 0.90 7.14 







QPKCNPN 508-514 2.60 7.04 





NPNLHYW 512-518 -7.60 7.02 





NP gene product YQSYSEN 469-475 -0.60 6.99 





HLGLDDQ 365-371 2.10 7.23 
DQEKKIL 370-376 8.60 6.99 
But the heptapeptide epitopes PSTPPQD, SHYEPPN, PDYDDCH, DYDDCHS and EYTYPDS did not contain even a single aliphatic amino acid.  
 
In silico analysis of the chemical properties (hydrophilicity, Gravy 
score for hydrophobicity, aromaticity, net charge at pH 7.0, pI i. e. 
Isoelectric point and polar/total amino acid ratio) for 
interrelationships of eight surface proteins revealed that Gravy 
score, isoelectric point and net charge at pH 7.0 showed a similar 
trend (Table 5). But hydrophobicity and isoelectric point of the 
proteins showed almost a reverse relationship (Fig 5). 
Peptide vaccines offer several advantages. Synthetic peptide-based 
vaccines administered subcutaneously in adjuvants are able to 
induce strong protective immunity against virus infections and 
malignancies as shown in several murine model systems [19-20]. 
Therefore, it is a novel strategy to stimulate immune response very 
purposefully based on a selected epitope or even a mixture of 
desired epitopes. Using a suitable adjuvant, peptide immunization 
could be a very straight forward method [18].  
Compared to the recombinant or attenuated viruses which are 
generally very powerful tools for immunization, the peptide-based 
vaccines do not run the risk of a back-mutation into a dangerous or 
potential virus as the former does.  
Not only are peptides easily produced at low cost, peptide vaccines 
do not need an uninterrupted cold preservation system.  
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Apart from the merits, a peptide-based vaccine is often associated 
with some demerits too. A peptide per se is usually not very 
immunogenic and therefore, the only solution is to choose a suitable 
adjuvant and carrier in order to protect the peptide from protease 
degradation and direct it into an immune response pathway.  
Furthermore, it may be hard to predict the outcome of a peptide-based 
vaccine at the initial stage. Depending on the antigen sequence, the dose 
and the route of application, the peptide immunization strategy could 
end up with tolerance in the vaccinated individuals, or an ordinary 
immune response, immunopathology or even autoimmunity.  
 
Table 4: Immunogenicity analysis of B cell epitopes against four Ebola viruses (Kolaskar & Tongaonkar approach) 
Ebola Virus  B cell Epitope (7mer) No. of Aliphatic amino acids* Immunogenicity Analysis of 7mer Epitopes 
Hydropathy index Chou-Fasman Conformation Ig value 
Bundibugyo Virus  PSTPPQD 0 6.40 1.34 8.58 
SHYEPPN 0 6.71 1.27 8.52 
SHTTPSP 0 5.84 1.25 7.30 
DPSSYYH 0 6.29 1.30 8.18 
Sudan Virus PDYDDCH 0 6.51 1.31 8.53 
DYDDCHS 0 6.40 1.30 8.32 
QGIPDHP 2 5.83 1.21 7.05 
RLGQGIP 4 4.80 1.09 5.23 
Tai Forest Virus QPKCNPN 1 6.66 1.33 8.86 
DPSSYYH 0 6.29 1.30 8.18 
NPNLHYW 1 5.96 1.18 7.03 
SSYYHTT 0 5.76 1.14 6.57 
Zaire Ebola Virus YQSYSEN 0 6.60 1.20 7.92 
EYTYPDS 0 6.31 1.20 7.57 
HLGLDDQ 3 5.43 1.08 5.86 
DQEKKIL 4 5.93 0.89 5.28 
*Aliphatic amino acids considered for analysis: A, G, I, K, L, V & M  
 
 
Fig. 4: Hydropathy index, Chou-Fasman conformation and immunogenicity (Ig) of B cell epitopes in Ebola 
 






Aromaticity Net charge 
 at pH 7 
pI Polar/Total aa 
Spike glycoprotein 9.53 -314.70 0.09 -7.21 3.20 0.30 
Glycoprotein 9.51 -276.80 0.08 -3.21 3.70 0.30 
Matrix protein 4.54 -20.60 0.06 3.60 8.05 0.25 
VP 40 4.54 -20.60 0.06 3.60 8.05 0.25 
Virion spike glycoprotein 9.52 -222.20 0.09 -4.17 3.70 0.28 
Spike glycoprotein precursor 9.52 -216.20 0.09 -3.22 3.70 0.28 
NP Gene Protein 10.44 -511.00 0.07 -38.94 3.70 0.37 
Virion Spike glycoprotein precursor 9.60 -261.80 0.09 -6.21 3.70 0.29 
[ 
 
Fig. 5: Chemical properties of eight surface proteins in Ebola virus 
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Virosomes have been successfully used in vaccine development. 
Virosomal vaccines against both influenza virus (Inflexal) and 
hepatitis A virus (Epaxal) already exist in the Swiss market [18]. 
Virosomes are in fact liposomes and seem to be suitable carriers or 
vectors for delivering various kinds of antigens such as peptides, 
proteins and inactivated viruses or even DNA.  
Moreover, the complex interactions among components of the 
vaccine are hard to predict and demand a through pre-clinical test 
program. Since no effective vaccine is yet available in the market as a 
prophylactic or therapeutic measure against Ebola virus, it is 
imperative to develop a multi-epitope peptide-based vaccine 
formulation against Ebola virus. Further research work may be 
initiated to understand the reactivity of these epitopes with human 
proteome.  
CONCLUSION 
The results of the present study suggest that a multiepitope peptide-
based vaccine may be formulated with a mixture of 4 hexapeptide 
(6-mer) epitopes i. e. RRKRRD, DEDDED, RRTRRE and KTGKKG and 
8 heptapeptide (7-mer) epitopes i. e. PTSPPQD, SHYEPPN, 
PDYDDCH, DYDDCHS, QPKCNPN, EYTYPDS, HLGLDDQ, and 
DQEKKIL with T-cell and B-cell targeting (signal) peptides in a virus 
like particle (vlp) by pharmaceutical industry followed by pre-
clinical tests to combat the spread of fatal Ebola virus in human 
population.  
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